Evoke Pharma Gross Profit

The latest gross profit for EVOK is $9.8M as of September 2025. That compares with $8.4M in the prior-year period — up 16.5% year over year. That is below the Healthcare sector average of $67B. Investors often review this figure alongside Evoke Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, EVOK's gross profit moved from $8.4M to $9.8M — a 16.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Evoke Pharma's operating scale or balance-sheet position.

Against Healthcare companies, EVOK currently prints $9.8M for gross profit, while the sector average sits near $67B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Evoke Pharma's growth, margins, and balance sheet.

A gross profit figure of $9.8M for EVOK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $67B. Explore the charts below for those layers of context.

After noting EVOK's gross profit ($9.8M), review year-over-year change from $8.4M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.